Pacira Announces FDA Approval of Expanded Exparel Label to Include Two Additional Nerve Block Indications
Exparel is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies—
New indications for use as an adductor canal block and sciatic nerve block in the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Study